Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Van Allen
Abstract B015: Clinical-stage ADC target enrichment across angiosarcoma anatomical subsets Free
Results: In HNFS (n=20), four ADC targets were enriched (FDR<0.05): HER3 (OR 13.1; 90%/80% at log2TPM≥3/≥5), TROP2 (OR 9.3; 85%/60%), Nectin-4 (OR 19.1; 80%/20%), L1CAM (OR 4.9; 35%/15%); HER2 and EGFR were borderline. HER2 appears least susceptible to keratinocyte admixture. Matching ADCs: sacituzumab govitecan/datopotamab deruxtecan (TROP2), patritumab deruxtecan (HER3), enfortumab vedotin (Nectin-4), trastuzumab deruxtecan (HER2).
Insider Trading Meets Prediction Markets: Six Steps Every Market Participant Should Take Now
By Tiffany E. Payne, Counsel, Litigation; P. Barrett Morris, Head of Swaps & Derivatives; and Nader Raja, Member, Litigation, Moore & Van Allen The enforcement landscape for prediction markets has shifted dramatically. In just five weeks, the Commodity Futures Trading Commission (CFTC) and the Department of Justice (DOJ) brought parallel civil and criminal insider trading cases against two individuals who traded event contracts on Polymarket, a prediction marketplace.
South Carolina Freezes Certain Nonprofit Low-Income Housing Property Tax Exemption Applications
Moore & Van Allen are most popular: within Media, Telecoms, IT and Entertainment topic(s) UPDATE — May 20, 2026: On May 19, 2026, the Governor signed S. 853 into law, enacting the temporary processing freeze on certain Exemption Statute applications discussed below. This is the second late-session bill affecting the nonprofit housing property tax exemption. As covered in our May 12, 2026, client alert, H.
USCIS Policy Memo On Adjustment Of Status
Moore & Van Allen’s articles from Moore & Van Allen are most popular: in Asia in Asia in Asia in Asia with readers working within the Insurance industries Moore & Van Allen are most popular: within Real Estate and Construction, Media, Telecoms, IT, Entertainment, Government and Public Sector topic(s) On Friday, May 22, 2026, the U.S. Citizenship and Immigration Services (USCIS) issued a new policy memo reminding immigration officers that the grant of an adjustment of status to lawful...
Client Alert: South Carolina Property Tax Exemption For Nonprofit Low-Income Housing: Critical Legislative Development
Moore & Van Allen are most popular: within Media, Telecoms, IT and Entertainment topic(s) Pending South Carolina legislation would unexpectedly amend the nonprofit housing property tax exemption statute. On May 7, 2026, the South Carolina Senate amended H. 5006 to include changes to the nonprofit housing property tax exemption under S.C. Code § 12-37-220(B)(11)(e) (the “Exemption Statute”). The bill, as amended, passed the Senate 46-0 and is now before the House for consideration.
What Companies Need from Modern Manufacturing Sites
It’s official — manufacturing projects are the hottest ticket in town. Manufacturing projects are among the most competitive investments in today’s site selection landscape. For companies evaluating expansion or relocation, a single manufacturing facility can represent a multiyear commitment of capital, labor and operational risk.
Abstract PR027: Spatial heterogeneity atlas of prostate cancer evolution (SHAPE): Spatial and genomic landscapes of advanced prostate cancer with and without Lu-PSMA therapy
Citation Martin K. Bakht, Jacob Egelberg, Yasutaka Yamada, Louise Clark, Xiao Wei, Varadha Balaji Venkadakrishnan, Anthony P. Belanger, Alice Bernard-Tessier, Sarah J. Hill, Francesca Khani, David J. Einstein, Mary-Ellen Taplin, Eliezer Van Allen, Heather A. Jacene, Himisha Beltran; Abstract PR027: Spatial heterogeneity atlas of prostate cancer evolution (SHAPE): Spatial and genomic landscapes of advanced prostate cancer with and without Lu-PSMA therapy.
Abstract PR001: Immune spatial organization predicts metastasis risk in aggressive localized prostate cancer
Citation David D. Yang, Aya Abdelnaser, Alexander J. Haas, Jeremiah Wala, Alfred A. Barney, Eddy Saad, Jett P. Crowdis, Cora A. Ricker, Seifeldin Awad, Bora Gurel, Jihye Park, Martin T. King, Paul L. Nguyen, Toni K. Choueiri, David J. Einstein, Steven P. Balk, Alok K. Tewari, Johann S. de Bono, Keyan Salari, Mary-Ellen Taplin, Chin-Lee Wu, Eliezer M. Van Allen; Abstract PR001: Immune spatial organization predicts metastasis risk in aggressive localized prostate cancer.
[2511.20680] Cognitive bias in LLM reasoning compromises interpretation of clinical oncology notes
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website. Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them. Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Sarah Byrne Honored with 2025 Pathbreaker Award by Shared Hope International
Moore & Van Allen (MVA) congratulates Sarah Byrne, Member and MVA Human Trafficking Pro Bono Project lead, on being named a 2025 Pathbreaker Award honoree by Shared Hope International. The Pathbreaker Award honors U.S.-based individuals and organizations who have carved essential routes to justice and hope for trafficking victims and survivors.
Immigration Client Alert - Registration Requirement
MV Moore & Van Allen More At Moore & Van Allen, representation extends beyond traditional legal services. We represent ideas, values and aspirations. We represent carefully laid plans and bold long-term goals. By immersing ourselves in a deep understanding of what is important and meaningful to our clients we bring clear perspective to any legal challenge and find solutions in unexpected places.
The Desk - February Edition
January is at least eight weeks – I'm certain of it. Now that it's February we know who's running the CFTC and its different Divisions, for the time being. Acting Chair Pham comes to her position with a long history of interesting and important dissents and other publications since becoming a In this month's newsletter we focus on a lengthy analysis of what may be coming based on Acting Chair Pham's dissents.
Cisplatin exposure dysregulates insulin secretion in male and female mice
This article contains supplementary material online at https://doi.org/10.2337/figshare.28184291. This content is only available via PDF. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer Open Access
Open figure viewer Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. Most patients present with advanced cancer and die within 12 months of diagnosis due to limited therapeutic options and poor responses to standard-of-care chemotherapy (1, 2). KRAS is the dominant oncogene in PDAC and is altered in more than 90% of tumors, with G12D, G12V, and G12R substitutions being most frequently observed (3, 4).
Genomic, clinical data, and scripts for PD-1 blockade resistance in metastatic melanoma
Methods Metastatic melanoma patients treated with immune checkpoint blockade were identified from published work (Liu et al. Nature Medicine 2019 & Freeman et al. Cell Reports Medicine 2022) and completed clinical trials (BMS Checkmate 038 and checkmate 064). We included only samples without prior exposure to ipilimumab, with WES data of the paired tumor and normal tissue obtained before PD1 blockade.
Toward a CRISPR-based mouse model of Vhl-deficient clear cell kidney cancer: Initial experience and lessons learned
Toward a CRISPR-based mouse model of Vhl-deficient clear cell kidney cancer: Initial experience and lessons learned Laura A. Stransky, Wenhua Gao, Laura S. Schmidt https://orcid.org/0000-0002-5050-5491, +29 , Kevin Bi, Christopher J. Ricketts, Vijyendra Ramesh, Amy James, Simone Difilippantonio, Lilia Ileva, Joseph D. Kalen, Baktiar Karim https://orcid.org/0000-0001-9604-9762, Albert Jeon, Tamara Morgan, Andrew C.
'The court giveth, and the court taketh away': the epitaph of the Chevron doctrine
(August 09, 2024) - Pierce Werner, Mary Katherine H. Stukes and Chassity Bobbitt of Moore & Van Allen analyze the decision overturning the Chevron case, the principles raised and the consequences.
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
This content is only available via PDF. This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License . Supplementary data Supplemental Figure 8 Immune cell functional states differ in clinical responders compared to non-responders.
Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions
3Harvard Medical School, Boston, Massachusetts. 4Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts. 5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 8Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts. Search for other works by this author on:
Directors and executives take note: Delaware court voids Elon Musk's $55B Tesla pay package
(February 8, 2024) - Bill Butler of Moore & Van Allen analyzes the decision of the Delaware Court of Chancery to void Elon Musk's pay package with Tesla, noting corporate governance standards and requirements regarding directors' conflict of interest. "Was the richest person in the world overpaid?" That is the question that the Delaware Court of Chancery answered in its Jan. 30, 2024, decision in the shareholder derivative action Tornetta v. Musk, et al., C.A. No. 2018-0408-KSJM, (Del. Ch. Jan.
Sarah Byrne recognized by North Carolina Human Trafficking Commission
Moore & Van Allen (MVA) Member Sarah Byrne was recognized by the North Carolina Human Trafficking Commission during a press conference hosted by Moore & Van Allen on January 23. North Carolina Attorney General Josh Stein, Charlotte-Mecklenburg Police Chief Johnny Jennings, District Attorney Spencer Merriweather, and anti-trafficking leaders discussed the fight against human trafficking in honor of National Human Trafficking Prevention Month.
Navigating data challenges and compliance in AI initiatives
(January 19, 2024) - Anup Iyer of Moore & Van Allen discusses legal challenges related to data privacy arising from AI and provides guidance for in-house counsel on establishing frameworks for responsible utilization of data in AI initiatives. Data serves as the foundational element for artificial intelligence (AI) models, enabling algorithms to discern patterns, forecast outcomes, and provide insights.
In Loper Bright and Relentless, Supreme Court returns to high-stakes question of viability of the Chevron doctrine
(November 7, 2023) - James P. McLoughlin Jr., Mary Katherine Stukes and Pierce Werner of Moore & Van Allen discuss the arguments, background and questions surrounding the Supreme Court's upcoming review of the Chevron doctrine. On May 1, 2023, the Supreme Court granted certiorari inLoper Bright Enterprises v. Raimondo, Case No. 21-5166.
Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Citation Sophia C. Kamran, Yuzhen Zhou, Keisuke Otani, Michael Drumm, Yukako Otani, Shulin Wu, Chin-Lee Wu, Adam S. Feldman, Matthew Wszolek, Richard J. Lee, Philip J. Saylor, Jochen Lennerz, Eliezer Van Allen, Henning Willers, Theodore S. Hong, Yang Liu, Elai Davicioni, Ewan A. Gibb, William U. Shipley, Kent W. Mouw, Jason A. Efstathiou, David T. Miyamoto; Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
Interplay of Mendelian and polygenic risk factors in Arab breast cancer patients
Genome Medicine, Sep 2023 Breast cancer patients from the indigenous Arab population present much earlier than patients from Western countries and have traditionally been underrepresented in cancer genomics studies. The contribution of polygenic and Mendelian risk toward the earlier onset of breast cancer in the population remains elusive.
Empirical evaluation of language modeling to ascertain cancer outcomes from clinical text reports
BMC Bioinformatics, Sep 2023 Longitudinal data on key cancer outcomes for clinical research, such as response to treatment and disease progression, are not captured in standard cancer registry reporting. Manual extraction of such outcomes from unstructured electronic health records is a slow, resource-intensive process. Natural language processing (NLP) methods can accelerate outcome annotation, but they require substantial labeled data.
Empirical evaluation of language modeling to ascertain cancer outcomes from clinical text reports - BMC Bioinformatics
The overall cohort for this analysis consisted of patients with cancer participating in a single-institution genomic profiling study [27], and relevant data consisted of imaging reports for each patient. Each report was treated as its own unit of analysis, and reports were divided, at the patient level, into training (80%), validation (10%), and test (10%) datasets. For language model pre-training on data from our institution, reports for all patients in the training set were included.
Interplay of Mendelian and polygenic risk factors in Arab breast cancer patients - Genome Medicine
AA-S, MA-J, YAM, FA, CV, AAN, AA, and AA-A are responsible for the acquisition of clinical data and the enrollment of patients. HC, SHA, SC, and SH created the computational pipeline and processed the genetic data. HC and SHA performed analysis and interpretation of data. HC and SHA drafted the manuscript. HC prepared the figures. AA-A, SHA, EVA, and RG performed critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.
Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer
Prostate cancer is the second leading cause of male cancer-related death in the United States (1) and the fifth leading cause of death worldwide (2). Whereas localized tumors can often be cured by definitive local therapy, advanced tumors represent an incurable disease. Most prostate cancer patients succumb to their disease because of metastatic spread.
Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
The signaling program regulated by the androgen receptor (AR) is an important therapeutic target for the treatment of metastatic prostate cancer (mPC) as it mediates critical cell survival, proliferation, and metabolic functions (1, 2). Treatment strategies center on suppressing AR signaling, either by androgen deprivation therapy (ADT), and/or administering AR signaling inhibitors (ARSI) including competitive antagonists (3–6).
Moving goalposts: U.S. Supreme Court narrows scope of federal protection for wetlands
(August 10, 2023) - Pierce Werner, Mary K. Stukes and Peter McGrath of Moore & Van Allen's environmental practice break down the significance of the high court's May 25 Sackett opinion limiting the Clean Water Act's regulatory reach. For years federal environmental regulation of waterways and wetlands has been in a state of flux, changing with political tides via agency rulemakings, but the Supreme Court of the United States may have just ended the cycle.
Drafting patent claims for AI-based inventions: navigating eligibility and precision
(August 7, 2023) - Anup Iyer and Nick Russell of Moore & Van Allen discuss issues over patent eligibility of artificial intelligence inventions as many AI innovations can be viewed as abstract since they involve algorithms and mathematical processes. In the rapidly evolving landscape of artificial intelligence (AI), innovation is at an all-time high.
Supreme Court dramatically expands scope of state court jurisdiction over businesses
(July 25, 2023) - Kyle Jacob and Jim McLoughlin of Moore & Van Allen discuss the Supreme Court's decision in Mallory v. Norfolk Southern Railway Co. holding registration to do business in a state is sufficient for personal jurisdiction even if the subject of the lawsuit has no connection to the state.
SCOTUS clarifies intent requirement for False Claims Act cases
(July 6, 2023) - Tanisha Palvia and Alli Davidson of Moore & Van Allen discuss the Supreme Court decision on the intent standard for False Claims Act violations and explore its implications. The circuit courts of appeal have been split on the intent standard for False Claims Act violations. On June 1, 2023, the Supreme Court in United States ex. rel. Schutte v. Supervalu Inc.
CFPB targets credit card late fees with lower safe harbor and elimination of annual inflation adjustment in new proposed rule
(February 23, 2023) - Moore & Van Allen attorneys Kate Wellman and Aishaah Reed Foster discuss the Consumer Financial Protection Bureau's proposal to lower the late fees credit card issuers can charge consumers and still qualify for a regulatory safe harbor. On February 1, 2023, the Consumer Financial Protection Bureau (CFPB) issued a notice of proposed rulemaking1 aimed at lowering the fees credit card issuers may charge consumers for making late payments on credit cards (the Proposed Rule).
CFPB issues proposed rule to require nonbank registration and public registry of terms and conditions in form contracts
(February 7, 2023) - Moore & Van Allen attorneys Barrett Morris, John Stoker and Ed Ivey discuss the Consumer Financial Protection Bureau's proposal to create a public registry of form contracts for financial products that purport to waive or restrict legal protections for consumers.
Examining the Use of Renewable Assignments in a Teacher Education Course to Build Understanding of Open Educational Resources
Examining the Use of Renewable Assignments in a Teacher Education Course to Build Understanding of Open Educational Resources Jennifer Van Allen [1] ; Stacy Katz [1] [1] Lehman College, City University of New York, US Localización: Open Praxis, ISSN-e 2304-070X, Vol. 14, Nº. 1, 2022, págs. 27-38 Idioma: inglés Enlaces Texto completo Despite a culture of sharing in education, awareness of Open Educational Resources (OER) in teacher education and K-12 education is limited.
PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner
hERV expression has been associated with both prognosis and ICB response in ccRCC (14, 15). To understand the underlying mechanism of hERV regulation in ccRCC, we asked whether genes mutated in ccRCC could influence hERV transcription. Herein we report that PBRM1 loss is associated with increased hERV expression, particularly the HERVERI superfamily. PRBM1's regulation of hERVs is specific to ccRCC and not seen in other TCGA tumor types.
Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset - Nature Communications
Abstract To accelerate cancer research that correlates biomarkers with clinical endpoints, methods are needed to ascertain outcomes from electronic health records at scale. Here, we train deep natural language processing (NLP) models to extract outcomes for participants with any of 7 solid tumors in a precision oncology study. Outcomes are extracted from 305,151 imaging reports for 13,130 patients and 233,517 oncologist notes for 13,511 patients, including patients with 6 additional cancer types.
Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology - Nature Cancer
Abstract Tumor molecular profiling of single gene-variant (‘first-order’) genomic alterations informs potential therapeutic approaches. Interactions between such first-order events and global molecular features (for example, mutational signatures) are increasingly associated with clinical outcomes, but these ‘second-order’ alterations are not yet accounted for in clinical interpretation algorithms and knowledge bases.
Biologically informed deep neural network for prostate cancer discovery - Nature
Abstract The determination of molecular features that mediate clinically aggressive phenotypes in prostate cancer remains a major biological and clinical challenge1,2. Recent advances in interpretability of machine learning models as applied to biomedical problems may enable discovery and prediction in clinical cancer genomics3,4,5.
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer - Nature Communications
Abstract Immune checkpoint inhibitors (ICIs) have minimal therapeutic effect in hormone receptor-positive (HR+ ) breast cancer.
Transcriptional mediators of treatment resistance in lethal prostate cancer - Nature Medicine
Abstract Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or acquired resistance to second-generation androgen-targeting therapies and minimal response to immune checkpoint inhibitors1. Cellular programs driving resistance in both cancer and immune cells remain poorly understood. We present single-cell transcriptomes from 14 patients with advanced prostate cancer, spanning all common metastatic sites.
Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
24 References 212 Citing Articles Related Articles Summary Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effective in treating tumors harboring alterations in the mTOR pathway. Mechanisms of resistance to everolimus remain undefined. Resistance developed in a patient with metastatic anaplastic thyroid carcinoma after an extraordinary 18-month response.
December Texas Books Preview
We’re still digesting the Thanksgiving feast as we eye the leftovers, football is blaring from the family room, and the forecast is chilly and damp. Obviously, it’s a good time to plan your gift list for online shopping—and we’ve got you.
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Abstract Treatment options for patients with metastatic melanoma, and especially BRAF-mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of eight new therapeutic agents. During this period, the treatment paradigm for BRAF-mutant disease has evolved rapidly: the standard-of-care BRAF-targeted approach has shifted from single-agent BRAF inhibition to combination therapy with a BRAF and a MEK inhibitor.
Genomic evolution and chemoresistance in germ-cell tumours
Abstract Germ-cell tumours (GCTs) are derived from germ cells and occur most frequently in the testes1,2. GCTs are histologically heterogeneous and distinctly curable with chemotherapy3. Gains of chromosome arm 12p and aneuploidy are nearly universal in GCTs4,5,6, but specific somatic genomic features driving tumour initiation, chemosensitivity and progression are incompletely characterized.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Van
Contact Van, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack